Grifols S.A. (GRFS) vs Mirum Pharmaceuticals (MIRM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Mirum Pharmaceuticals (MIRM) has outperformed Grifols S.A. (GRFS) over the past year, gaining 9.4% versus a loss of 21.8%. Over five years, MIRM leads with a +371.0% price change compared with -47.3% for GRFS. Mirum Pharmaceuticals is the larger company by market cap ($5.24 billion vs $5.10 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | MIRM |
|---|---|---|
| Share price | $7.50 | $80.64 |
| Market cap | $5.10B | $5.24B |
| 1-day change | -0.27% | +1.75% |
| YTD return | -19.79% | +2.09% |
| 1-year return | -21.79% | +9.36% |
| 5-year return | -47.26% | +371.03% |
| P/E ratio (TTM) | 9.74 | — |
| Forward P/E | 5.20 | — |
| EPS (TTM) | $0.77 | $-14.10 |
| Dividend yield | 1.41% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $521.31M |
| Revenue growth (YoY) | — | +54.74% |
| Net income (latest FY) | — | $-23.36M |
| Operating margin | — | -4.25% |
| Net margin | — | -4.48% |
| 52-week high | $9.90 | $130.00 |
| 52-week low | $6.96 | $63.23 |
| Distance from 52-week high | -24.24% | -37.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.93% | +80.79% |
| Average volume | 583.27K | 693.63K |
| Shares outstanding | 258.22M | 64.93M |
| Employees | 25,258 | 433 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MIRM has outperformed GRFS by 31.2 percentage points over the past year.
- Grifols S.A. offers a meaningfully higher dividend yield (1.41% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About Mirum Pharmaceuticals
MIRM stock →Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 433 employees
GRFS vs MIRM FAQ
Which is bigger, Grifols S.A. or Mirum Pharmaceuticals?
Mirum Pharmaceuticals (MIRM) is larger, with a market capitalization of $5.24B compared with $5.10B for Grifols S.A. (GRFS).
Which stock has performed better over the past year, GRFS or MIRM?
MIRM returned +9.36% over the past 12 months, compared with -21.79% for GRFS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Grifols S.A. or Mirum Pharmaceuticals?
Grifols S.A. pays a dividend yielding 1.41%, while Mirum Pharmaceuticals does not currently pay a regular dividend.
Are Grifols S.A. and Mirum Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.